EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 736 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem November 2, 2022 Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... April 16, 2019 Why Wearing Comfortable Clothes During Cancer Treatment Matters October 21, 2021 ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... April 16, 2015 Load more HOT NEWS Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... Cancer in My Community: Bringing Palliative Care to People With Cancer... ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...
